Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of gildeuretinol in patients with Stargardt disease

Next Previous
Trial Profile

Study of gildeuretinol in patients with Stargardt disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gildeuretinol (Primary)
  • Indications Stargardt disease
  • Focus Therapeutic Use
  • Acronyms TEASE-2

Most Recent Events

  • 09 Oct 2025 Status changed from active, no longer recruiting to completed as per Alkeus Pharmaceuticals Media Release,
  • 09 Oct 2025 According to the Alkeus Pharmaceuticals Media Release, data from this trial will be presented at the 129th annual meeting of the American Academy of Ophthalmology (AAO
  • 11 Feb 2025 According to the Alkeus Pharmaceuticals Media Release, safety and efficacy results from TEASE program will be presented at the 48th Annual Meeting of the Macula Society being held February 12-15 in Charlotte Harbor, Fla.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top